Sino Biopharmaceutical Net Income 2018-2021 | SBMFF

Sino Biopharmaceutical net income from 2018 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Sino Biopharmaceutical Annual Net Income
(Millions of US $)
2020 $402
2019 $392
2018 $1,367
2016 $246
Sino Biopharmaceutical Quarterly Net Income
(Millions of US $)
2021-06-30
2021-03-31 $295
2020-03-31 $124
2019-03-31 $127
2018-03-31 $121
2017-03-31 $84
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $3.426B
Sino Biopharmaceutical Limited researches, develops, produces and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis. Sino Biopharmaceutical Limited is headquartered in Wanchai, Hong Kong.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69